[Anabolic effects of statin and beta-blocker on bone metabolism].
Recent studies suggest that statins and beta-blockers which are widely prescribed for the treatment of hyperlipidemia and hypertension play an important role in bone metabolism. Statins inhibit HMG-CoA reductase and its down-stream mevalonate pathway. They modulate osteoclastic and osteoblastic activity, since metabolites of mevalonate are critically involved in bone cell biology. Sympathetic nervous system also controls bone formation via its direct effects on osteoblasts. Administration of beta-blockers may lead to an increase bone mass and reduce the risk of fracture. Statins and beta-blockers could have anabolic effects on bone metabolism and may be potential therapeutic implications for osteoporosis.
Taguchi
Manabu
M
Department of Endocrinology and Metabolism, Toranomon Hospital.
Takeuchi
Yasuhiro
Y
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000378:metabolism*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D008798:Mevalonic Acid / Q000378:metabolism; D010006:Osteoblasts / Q000502:physiology; D010010:Osteoclasts / Q000502:physiology; D010012:Osteogenesis / Q000187:drug effects; D010024:Osteoporosis / Q000150:complications / Q000517:prevention & control; D012306:Risk; D013268:Stimulation, Chemical; D013564:Sympathetic Nervous System / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008798:Mevalonic Acid